{
  "id": "6020af2e1cb411341a000084",
  "type": "factoid",
  "question": "What disease is treated with BIVV001?",
  "ideal_answer": "BIVV001 fusion protein has been developed as Factor VIII replacement therapy for hemophilia A",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32078672",
    "http://www.ncbi.nlm.nih.gov/pubmed/32905674"
  ],
  "snippets": [
    {
      "text": "BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32078672",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We have developed a new class of FVIII replacement, rFVIIIFc-VWF-XTEN (BIVV001), that is physically decoupled from endogenous VWF and has enhanced pharmacokinetic properties compared with all previous FVIII products",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32078672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BIVV001 is the first rFVIII with the potential to significantly change the treatment paradigm for severe hemophilia A by providing optimal protection against all bleed types, with less frequent doses. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32078672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905674",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": ". BIVV001 (rFVIIIFc-VWF-XTEN) is a novel fusion protein designed to overcome this half-life ceiling and maintain high sustained factor VIII activity levels. Data are lacking on the safety and pharmacokinetics of single-dose BIVV001.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In a small, early-phase study involving men with severe hemophilia A, a single intravenous injection of BIVV001 resulted in high sustained factor VIII activity levels, with a half-life that was up to four times the half-life associated with recombinant factor VIII, an increase that could signal a new class of factor VIII replacement therapy with a weekly treatment interval.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905674",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BIVV001 is the first rFVIII with the potential to significantly change the treatment paradigm for severe hemophilia A by providing optimal protection against all bleed types, with less frequent doses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32078672",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Hemophilia A"
}